Dergiler / Eurasian Journal of Medical Investigation / 2019 / Cilt: 3 - Sayı: 2

The Retrospective Evaluation of Hodgkin lymphoma Cases and The Effects of Prognostic Factors on Survival:A Seven-year-experience

Sayfa
156–162
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

So, the progression risk of the toxidity and treatment complication in long term can be minimized.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: In this study, we aimed to present the demographical, histopathological and clinical features of the cases diagnosed as Hodgkin lymphoma; and to determine the effects of negative prognostic grouping in early stage (stage I-II) of Hodgkin lymphoma and International Prognostic Score in late stage (stage III-IV) Hodgkin lymphoma on the survival of the patients.Methods: The data of the 46 patients diagnosed with Hodgkin lymphoma followed in our center for seven years has been evaluated retrospectively.Results: Demographical, histopathological and clinical features of the cases are shown in the table 1.
📊
Temel Bulgular & Veri:The primary treat-ments were %80.4 ABVD combination chemotheraphy and %19.6 chemotheraphy+radiotheraphy.
💡
Sonuç & Katkı:So, the progression risk of the toxidity and treatment complication in long term can be minimized.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: In this study, we aimed to present the demographical, histopathological and clinical features of the cases diagnosed as Hodgkin lymphoma; and to determine the effects of negative prognostic grouping in early stage (stage I-II) of Hodgkin lymphoma and International Prognostic Score in late stage (stage III-IV) Hodgkin lymphoma on the survival of the patients.Methods: The data of the 46 patients diagnosed with Hodgkin lymphoma followed in our center for seven years has been evaluated retrospectively.Results: Demographical, histopathological and clinical features of the cases are shown in the table 1. The primary treat-ments were %80.4 ABVD combination chemotheraphy and %19.6 chemotheraphy+radiotheraphy. Treatment methods and disease response rates are shown in the table 2. It was identified that there was an early relapse in the %69 and a late relapse in the %31 of the patients whose diseases relapsed after the primary treatment. The autologous stem cell transplants were done for the %60 of the patients. The median follow-up time was 22 months (change between 4-70). The rate of 5-year-overall survival (OS) was %87 and the rate of the relapse-free survival (RFS) was %71.7. As there was a significant difference between the genders in terms of OS rates, there was not for RFS rates (resp., p=0.01; p=0.07). When the patients were examined due to their responses to the primary treatment, there was a significant difference OS and RFS rates (p=0.002; p0.05). Moreover, in our study, no significant differ-ence among International Prognostic Score, OS and RFS rates was found.Conclusion: The treatment chart must be designed as taking the stage of the disease and the prognostic factors into consideration. So, the progression risk of the toxidity and treatment complication in long term can be minimized.

🔖

Bu Makaleye Atıf Yap

KELKİTLİ, E., ATAY, M. H., TURGUT, M., OZTURAN, A. (2022). The Retrospective Evaluation of Hodgkin lymphoma Cases and The Effects of Prognostic Factors on Survival:A Seven-year-experience. Eurasian Journal of Medical Investigation, Cilt: 3 - Sayı: 2, 156–162. https://ajindex.com/articles/508758

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 1832;17:69–97
  2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010 CA Cancer J Clin 2010;60:277–300
  3. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence. Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, version 2.0, Lyon (France): IARC Press, 2004
  4. Hoppe RT, Mauch PT, Armitage JO, et al. Hodgkin Lymphoma: 2 nd. Philadelphia: Lippincott Williams and Wilkins; 2007
  5. Kılıçkap S. Hacettepe Üniversitesi Onkoloji Enstitüsü Medikal Onkoloji Bölümü’nde takip edilen Hodgkin lenfoma olgularının klinikopatolojik özellikleri. Hacettepe Üniversitesi Onkoloji En-stitüsü Medikal Onkoloji Bilim Dalı Tezi, Ankara: 2009
  6. Seker M, Mengi A, Bilici A, Ustaalioğlu B, Kefeli U, Özseker N, et al. Hodgkin lenfoma olgularının retrospektif değerlendirilmesi ve prognostik faktörlerin saptanması Türk Onkoloji Dergisi 2011;26:108–114
  7. Altıntaş A, Çil T, Kaplan M, Atay A Işıkdoğan, et al. Hodgkin Lenfoma Olgularımız: Klinik ve Patolojik Değerlendirme. Ulus-lararası Hematoloji Onkoloji Dergisi 2006;16:165-171
  8. Coşkun HŞ, Er Ö, Eser B, Çetin M, Altınbaş M, Soyuer S, et al. Erken evre Hodgkin hastalığı: Erciyes Üniversitesi deneyimi. Erciyes Tıp Dergisi 2002;24:120–5
  9. Correa P, O'Conor GT, Berard CW, Axtell LM and Myers MH: International comparability and reproducibility in histologic subclassification of Hodgkin's disease. J Natl Cancer Inst 1973;50:1429–35
  10. Alexander FE, McKinney PA, Williams J, et al. Epidemiological evidence for the two-disease hypothesis in Hodgkin's disease. Int J Epidemiol 1991;20:354–61
  11. Alexander FE, Ricketts TJ, McKinney PA, et al. Community life-style characteristics and incidence of Hodgkin's disease in young people. Int J Cancer 1991;48:10–4
  12. Diehl V, Re D, Josting A. Hodgkin’s disease: Clinical manifes-tation, staging, and therapy. In: Hematology Basic Principle and Practice. Hoffman R, Benz EJ, Shattil S, Furie B, Cohen HJ, Silberstein LE, McGlave P (eds). 4th ed. Philadelphia, Elsevier Churchill Livingstone, 2005:1347–77
  13. MacLennan KA, Bennett MH, Tu A, et al. Relationship of his-tologic features to survival and relapse in nodular scleros-ing Hodgkin’s disease. A study of 1659 patients. Cancer 1989;64:1686–93
  14. Coskun HS, Eser B, Cetin M, et al. Hodgkin Disease: Results of single center in Central Anatolia of Turkey. Proc Am Soc Clin Oncol 2000;163
  15. Stein RS. Hodgkin’s Disease. In: Lee R